5 results
To determine whether addition of selexipag to current PAH therapy improves exercise capacity, imaging parameters and quality of life, delays time-to-first-PAH-related morbidity and mortality, prevents worsening of World Health Organization…
Primary goal:The cure at 12 monthsSecondary goals:1. Cough Stress Test (HST): objective endpoint2. Question 3 of the UDI-6 questionnaire: subjective endpoint3. Primary endpoint at 6 weeks, 6 months, and 36 months 24maanden4. Reduction of urine loss…
Objectives:To assess the safety of transitioning subjects to Raptiva therapy from standard oral systemic or phototherapy by overlapping with Raptiva whilst tapering the initial systemic therapy or phototherapy dose. The secondary objective is to…
The overall aim of the study is to evaluate the difference in speech performance of a new hands-free speech valve as compared to the currently most used (Atos) exhalation speech valve.
To explore the efficacy and safety of an oral IP receptor agonist in an inoperable or persistent/recurrent CTEPH population treated with standard of care.